MicroRNA and Posttranscriptional Dysregulation in Psychiatry  by Geaghan, Michael & Cairns, Murray J.
iological
sychiatryReview BPMicroRNA and Posttranscriptional Dysregulation
in Psychiatry
Michael Geaghan and Murray J. CairnsABSTRACT
Psychiatric syndromes, including schizophrenia, mood disorders, and autism spectrum disorders, are characterized
by a complex range of symptoms, including psychosis, depression, mania, and cognitive deﬁcits. Although
the mechanisms driving pathophysiology are complex and remain largely unknown, advances in the understanding
of gene association and gene networks are providing signiﬁcant clues to their etiology. In recent years, small
noncoding RNA molecules known as microRNA (miRNA) have emerged as potential players in the pathophysiology
of mental illness. These small RNAs regulate hundreds of target transcripts by modifying their stability and translation
on a broad scale, inﬂuencing entire gene networks in the process. There is evidence to suggest that numerous
miRNAs are dysregulated in postmortem neuropathology of neuropsychiatric disorders, and there is strong genetic
support for association of miRNA genes and their targets with these conditions. This review presents the
accumulated evidence linking miRNA dysregulation and dysfunction with schizophrenia, bipolar disorder, major
depressive disorder, and autism spectrum disorders and the potential of miRNAs as biomarkers or therapeutics for
these disorders. We further assess the functional roles of some outstanding miRNAs associated with these
conditions and how they may be inﬂuencing the development of psychiatric symptoms.
Keywords: Autism, Bipolar Disorder, Depression, miRNA, Psychiatry, SchizophreniaISShttp://dx.doi.org/10.1016/j.biopsych.2014.12.009MicroRNAs (miRNAs) have emerged as prospective players
in the pathophysiology of psychiatric disease. These small
noncoding RNA molecules have the capacity to regulate the
expression of many genes simultaneously and inﬂuence
cellular functions at the pathway level. This capacity makes
miRNAs potentially very signiﬁcant in the context of complex
neurodevelopmental syndromes, such as schizophrenia (SZ)
and other neuropsychiatric disorders.
The miRNA genes are dispersed throughout the
genome, often set apart from protein-coding genes, although
many are intronic (1–3). After transcription, the hairpin in the
primary miRNA transcript is recognized and cleaved into
an 70-nt precursor miRNA by the microprocessor complex
consisting of Drosha (an RNase III) and DGCR8 ((DiGeorge
syndrome critical region 8) (Figure 1) (4,5). These are trans-
located to the cytoplasm where Dicer (another RNase III)
removes the hairpin loop, leaving an 22-nt double-
stranded RNA. One strand of the mature miRNA is
loaded into the RNA-induced silencing complex, containing
Dicer, TAR RNA binding protein, and a member of the
Argonaute family (6). In many cases, either strand can become
the functional mature miRNA, with the sufﬁx “-3p” or “-5p”
added to the name to distinguish between the strands
derived from the precursor’s 30 and 50 ends, respectively
(7). The miRNA–RNA-induced silencing complex binds to
the 30 untranslated region of a messenger RNA target
through complementarity to nucleotides 2–8—the “seed
region”—of the miRNA (8) and destabilizes the transcript, or& 2015 Society of Biological Psychiatry. Th
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SEE COMMENTArepresses its translation, often followed by degradation, mak-
ing it possible to assess miRNA function via gene expression
proﬁling (9,10).
The importance of miRNAs and their biogenesis to the
developing brain has been known for almost a decade,
with a study demonstrating that zebraﬁsh depleted of
functional DICER protein display severe developmental abnor-
malities, particularly in the brain (11). These mutants
developed asymmetrically, with severely reduced ventricle
size and no midbrain-hindbrain boundary. Similarly, mice with
selective Dicer deletion in excitatory forebrain neurons dis-
played enlarged lateral ventricles associated with increased
postnatal cell death, decreased dendritic branching, abnor-
mally long dendritic spines, and loss of axonal pathﬁnding (12).
Additionally, these relatively short-lived mutants were micro-
cephalic and displayed ataxia. When Dicer is lost from
dopamine D1 receptor neurons in the striatum, mice have a
decreased life span, smaller brain size and mass, and smaller
medium spiny neurons and show ataxia and astrogliosis (13).
These studies demonstrate that miRNA biogenesis is
extremely important for normal brain development and
function.
In this review, we revisit some of the recent highlights in the
neurobiology of miRNA associated with neuropsychiatric
syndromes and examine the support for their involvement in
psychiatric pathophysiology. We also discuss the possible
clinical applications for miRNAs in psychiatric treatment and
what is needed for the ﬁeld to progress.is is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Figure 1. MicroRNA (miRNA) structure, biogenesis, and function. RNA polymerase II transcribes the primary miRNA transcript, which is processed in the
nucleus by Drosha and the microprocessor complex into the 70-nt precursor miRNA hairpin. This hairpin is exported to the cytoplasm by Exportin-5 and
Ran-GTP, where Dicer cuts off the loop end of the hairpin, leaving an 22-nt long, imperfectly base-paired RNA duplex. One of these strands is the mature
miRNA, which is loaded into the RNA-induced silencing complex, which then mediates the silencing of messenger RNA molecules, which are targeted based
on complementarity to the loaded miRNA. The RNA-induced silencing complex silences gene expression by inhibiting translation through interference 50 cap-
binding protein interactions or degrading the target messenger RNA by compromising its stability through poly(A) tail deadenylation, 50 cap loss, and
exoribonuclease degradation. DGCR8, DiGeorge syndrome critical region 8; mRNA, messenger RNA; pre-miRNA, precursor microRNA; pri-miRNA, primary
microRNA transcript; RISC, RNA-induced silencing complex.
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PSYCHIATRIC DISORDERS
In view of the vital role for miRNAs in the brain, it is not
surprising that they are also emerging as signiﬁcant players
in the pathophysiology of several neurologic conditions.
There is substantial research supporting the dysregulation
of miRNA in psychiatric syndromes from expression studies
that use microarrays and quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) analyses and genetic
association studies that identify single nucleotide polymor-
phisms (SNPs) and copy number variations (CNVs). Expres-
sion studies have typically used either postmortem brain or
other tissue samples such as peripheral blood mononuclear
cells. Although postmortem brain samples provide direct
evidence of miRNA dysregulation within the brain, peripheral
tissue samples can be obtained from living subjects and
have the potential to yield biomarkers that could be used as
diagnostic tools. Genetics studies do not assess miRNA
expression levels, but they present evidence for a causative
role for miRNAs in psychiatric illness; in contrast, expres-
sion studies can demonstrate only a correlation between
miRNAs and disease. We review the evidence linking SZ,
bipolar disorder (BD), major depressive disorder (MDD), and
autism spectrum disorders (ASDs) with altered miRNA
expression and genetic variations that interfere with miRNA
function.232 Biological Psychiatry August 15, 2015; 78:231–239 www.sobp.orgSZ
The association between miRNA dysfunction and SZ has been
reported in several studies (Table S1 in Supplement 1). One of
the earliest expression studies investigated postmortem brain
tissue from the dorsolateral prefrontal cortex (DLPFC) Brod-
mann area (BA) 9 (14). Using a custom microarray, the authors
identiﬁed 16 signiﬁcantly differentially expressed miRNAs in
subjects with SZ compared with control subjects including
miR-26b, miR-30a-5p, miR-30b/d/e, miR-29a/b/c, miR-195,
miR-92, miR-20b, miR-212, miR-7, miR-24, miR-9-3p, and
miR-106b. Only miR-106b was upregulated leaving the
remaining 15 miRNAs downregulated, 7 of which were also
conﬁrmed by qRT-PCR in a small subcohort. Using a similar
approach, we investigated postmortem miRNA levels in the
DLPFC (BA9) and the superior temporal gyrus (BA22) (15,16).
Among numerous miRNA species showing elevated expres-
sion was miR-107 and members of the miR-15 family (miR-
15a/b, miR-16, and miR-195), which all share similar seed
regions and common target genes and roles in neuronal
function, including neuronal proliferation and differentiation,
making them important with regard to the neurodevelopmental
aspect of SZ (Supplement 1) (17,18). Members of this family
have been identiﬁed in other psychiatric disorders (Table 1).
Additionally, the miRNA biogenesis gene DGCR8 was found to
be upregulated, suggesting that miRNA biogenesis was
increased and responsible for the global elevation of miRNA./journal
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by the hemizygous deletion of 22q11.2 deletion syndrome,
which predisposes individuals to DiGeorge syndrome and a
high risk of developing SZ (19,20). We also observed an
upregulation of miRNAs in SZ, including miR-107 again,
alongside an upregulation of the miRNA biogenesis gene
Dicer in the DLPFC (BA46) (21).
Although these analyses suggest that miRNAs are impor-
tant in the etiology of SZ, there is signiﬁcant heterogeneity and
some direct conﬂicts among studies. For example, in contrast
to the study by Perkins et al. (14), we observed miR-26b, miR-
29c, and miR-195 to be upregulated in BA9 (15). Kim et al. (22)
also analyzed postmortem tissue from the DLPFC (BA46)
using a TaqMan Low Density Array (TLDA; Applied Biosystems
Waltham, Massachusetts) and observed a discrepancy among
individuals concerning the direction of dysregulation. On
average, however, they discovered seven miRNAs were sig-
niﬁcantly upregulated (miR-34a, miR-132, miR-132*, miR-212,
miR-544, miR-7, and miR-154*). In contrast, miR-212 was
observed to be downregulated by Perkins et al. (14). The
dysregulation of miR-312 and miR-212 is also particularly
signiﬁcant because these miRNAs are part of a cluster that has
been identiﬁed in other psychiatric disorders. These miRNAs
also have known functions in the brain, including regulating
synaptic transmission and plasticity in the hippocampus and
neocortex (23) and regulating memory formation (24). These
miRNAs have been the focus of many studies and have
particular relevance to SZ and MDD (Supplement 1). Other
miRNAs species have also been associated with SZ and other
psychiatric disorders on multiple occasions (Table 1), and
despite conﬂicting ﬁndings, patterns are emerging with
signiﬁcance to SZ.
Analysis of miRNA expression in peripheral tissues has also
revealed associations with SZ. We explored miRNA expres-
sion in peripheral blood mononuclear cells using a microarray
and qRT-PCR and observed 83 downregulated miRNAs in SZ
with a false discovery rate ,5% (25). Of these, 17 came from
the imprinted DLK1-DIO3 region at the 14q32 locus and are
part of many maternally expressed miRNA clusters in the
region (26). Transcription of the larger miR-379/410 cluster is
induced by neuronal activity, suggesting their importance in
neuronal function (27). In a similar study, Lai et al. (28)
observed six upregulated miRNAs by TLDA and qRT-PCR,
including miR-449a, miR-564, miR-432, miR-548, miR-572,
and miR-652, and one downregulated miRNA (miR-34a). In an
analysis of serum miRNA expression by qRT-PCR, Shi et al.
(29) found miR-195 downregulated, whereas miR-181b, miR-
219-2-3p, miR-1308, and let-7g were upregulated. These
studies demonstrate the potential of peripheral biomarkers
for psychiatric disease.
Numerous SNPs in miRNA genes have been associated with
SZ. In one of the largest genome-wide association studies of SZ
undertaken by the Psychiatric Genome Consortium, with 17,836
cases and 33,859 controls, the SNP rs1625579 within the intron
for a putative primary transcript of miR-137 was the strongest
new association with SZ (30). Four other loci associated with SZ
in the same study were also predicted targets of miR-137,
supporting the functional signiﬁcance of this regulatory network
in SZ. More recently, the Psychiatric Genome Consortium
conﬁrmed the association within the MIR548AJ2 gene inBiological Psy36,989 cases and 113,075 controls (31). Further research into
miR-137 revealed numerous functional implications relevant to
the etiology of SZ, including a role in proliferation and differ-
entiation of neuronal stem cells in the developing brain (32) and
roles in glutamatergic and GABAergic signaling and long-term
potentiation (33). The risk allele rs1625579 has been observed to
correspond with reduced miR-137 expression in the DLPFC and
hyperactivation of this region (Supplement 1) (34,35). Another
SZ-associated SNP, rs3822674, has been identiﬁed and found
to affect a binding site of miR-498 in the 30 untranslated region
of complexin 2 (CPLX2) (36). Using a luciferase assay, the
T allele at this SNP was found to induce translational repression
in the presence of miR-498, whereas the C allele prevented
repression. This C allele, in combination with the C and T alleles
of SNPs rs1366116 and rs3892909 (also within CPLX2), was
associated with the poorest cognitive performance within the
study. This effect on cognitive function in mice was observed
only after minor brain lesions were applied during puberty,
supporting a developmental two-hit hypothesis of SZ (37).
Environmental factors can also inﬂuence miRNA levels and
have implications for SZ. For example, maternal immune
activation (MIA) in animals using polyriboinosinic-polyribo-
cytidilic acid (poly-I:C) is an important tool for studying the
role of maternal infections in pathophysiology of SZ and
causes phenotypic abnormalities in the offspring that mimic
SZ. We identiﬁed 21 miRNA species that were differentially
expressed after MIA treatment in rats (38). In the same study,
we treated poly-I:C control adolescent rats with the cannabi-
noid receptor (CB1) agonist HU210 as a model for human
adolescent cannabis exposure and observed dysregulation of
seven miRNA species, most of which were also observed to
be dysregulated in the MIA group. Finally, a two-hit model in
which poly-I:C-affected rats were exposed to HU210 during
adolescence produced 18 differentially expressed miRNA
species. Target prediction of these 18 miRNAs revealed
potential roles in mitogen-activated protein kinase signaling,
important for neuronal development and cognition (39), and
the Wnt signaling pathway, also important in neuronal devel-
opment and SZ (40). This study highlights the ability of
environmental factors to inﬂuence miRNA expression, which
may have a role to play in the etiology of SZ.BD
Emerging research links miRNAs to BD with several studies
showing signiﬁcant alterations in miRNA expression levels in
postmortem cortical brain tissue from affected individuals
(Table S1 in Supplement 1). A few of these studies were run
in parallel alongside SZ studies discussed in the preceding
section. Kim et al. (22) used another TLDA array to analyze
postmortem DLPFC tissue samples of individuals with BD and
healthy control subjects (BA46) and identiﬁed seven miRNAs
(miR-504, miR-145, miR-145*, miR-22*, miR-133b, miR-154*,
and miR-889) to be upregulated, with a further eight miRNAs
(miR-454*, miR-29a, miR-520c-3p, miR-140-3p, miR-767-5p,
miR-874, miR-32, and miR-573) downregulated in individuals
with BD compared with control subjects. Moreau et al. (41)
also analyzed miRNA expression in BD with multiplexed qRT-
PCR alongside their SZ study and found a slight trend toward
downregulation of miRNA expression, with 24 miRNAschiatry August 15, 2015; 78:231–239 www.sobp.org/journal 233
Table 1. Psychiatric Disease–Associated miRNAs Identiﬁed by Multiple Studies
miRNA Authors miRNA Authors
Schizophrenia Major Depressive Disorder
miR-106ba Perkins et al., 2007 (14); Moreau et al., 2011 (41);
Smalheiser et al., 2014 (43)
miR-107a Smalheiser et al., 2011 (53); Belzeaux et al., 2012 (85)
miR-107a Beveridge et al., 2010 (15); Santarelli et al., 2011 (21) miR-125a Smalheiser et al., 2011 (53); Cao et al., 2013 (86)
miR-132a Kim et al., 2010 (22); Miller et al., 2012 (42) miR-132a Smalheiser et al., 2011 (53); Li et al., 2013 (56)
miR-132* Kim et al., 2010 (22); Miller et al., 2012 (42) miR-142-3p Smalheiser et al., 2011 (53); Smalheiser et al., 2012 (52)
miR-134 Santarelli et al., 2011 (21); Gardiner et al., 2012 (25) miR-145a Smalheiser et al., 2011 (53); Belzeaux et al., 2012 (85)
miR-137 Ripke et al., 2011 (30); Whalley et al., 2012 (45);
Green et al., 2013 (79)
miR-182 Smalheiser et al., 2011 (53); Li et al., 2013 (56);
Cao et al., 2013 (86)
miR-150 Santarelli et al., 2011 (21); Miller et al., 2012 (42) miR-200c Smalheiser et al., 2011 (53); Belzeaux et al., 2012 (85)
miR-15aa Beveridge et al., 2010 (15); Moreau et al., 2011 (41) miR-298 Smalheiser et al., 2011 (53); Cao et al., 2013 (86)
miR-16 Beveridge et al., 2010 (15); Smalheiser et al., 2014 (43) miR-376a* Smalheiser et al., 2011 (53); Smalheiser et al., 2012 (52);
Belzeaux et al., 2012 (85)
miR-17a Santarelli et al., 2011 (21); Wong et al., 2013 (80);
Smalheiser et al., 2014 (43)
miR-381 Smalheiser et al., 2011 (53); Belzeaux et al., 2012 (85)
miR-181b Beveridge et al., 2008 (16); Beveridge et al., 2010 (15);
Shi et al., 2012 (29)
miR-494 Smalheiser et al., 2012 (52); Belzeaux et al., 2012 (85)
miR-195a Perkins et al., 2007 (14); Beveridge et al., 2010 (15);
Shi et al., 2012 (29)
miR-497 Smalheiser et al., 2011 (53); Smalheiser et al., 2012 (52)
miR-212 Perkins et al., 2007 (14); Kim et al., 2010 (22) Autism Spectrum Disorders
miR-219-3p Shi et al., 2012 (29); Smalheiser et al., 2014 (43) miR-106ba Abu-Elneel et al., 2008 (59); Sarachana et al., 2010 (62)
miR-24 Perkins et al., 2007 (14); Xu et al., 2010 (81) miR-1286 Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-26b Perkins et al., 2007 (14); Beveridge et al., 2010 (15) miR-1306 Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-29ca Perkins et al., 2007 (14); Beveridge et al., 2010 (15) miR-132a Abu-Elneel et al., 2008 (59); Talebizadeh et al., 2008 (61);
Sarachana et al., 2010 (62)
miR-30b Perkins et al., 2007 (14); Mellios et al., 2012 (82) miR-146b Abu-Elneel et al., 2008 (59); Talebizadeh et al., 2008 (61)
miR-30e Perkins et al., 2007 (14); Xu et al., 2010 (81) miR-148ba Abu-Elneel et al., 2008 (59); Sarachana et al., 2010 (62)
miR-320 Tabares-Seisdedos et al., 2009 (83); Miller et al., 2012 (42) miR-149 Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-34a Kim et al., 2010 (22); Lai et al., 2011 (28) miR-17a Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
miR-432 Lai et al., 2011 (28); Gardiner et al., 2012 (25) miR-185 Sarachana et al., 2010 (62); Vaishnavi et al., 2013 (67);
Marrale et al., 2014 (68)
miR-544 Kim et al., 2010 (22); Gardiner et al., 2012 (25) miR-18a Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
miR-652 Lai et al., 2011 (28); Santarelli et al., 2011 (21) miR-195a Sarachana et al., 2010 (62); Vaishnavi et al., 2013 (67)
miR-7 Perkins et al., 2007 (14); Beveridge et al., 2010 (15);
Kim et al., 2010 (22)
miR-199b-5p Sarachana et al., 2010 (62); Ghahramani Seno et al., 2011 (63)
Bipolar Disorder miR-19a Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
let-7b Miller et al., 2012 (42); Shih et al., 2012 (84) miR-19b-1 Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
miR-106ba Moreau et al., 2011 (41); Shih et al., 2012 (84);
Smalheiser et al., 2014 (43)
miR-200a Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-132a Miller et al., 2012 (42); Whalley et al., 2012 (45) miR-200b Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-133b Kim et al., 2010 (22); Shih et al., 2012 (84) miR-20a Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
miR-145a Kim et al., 2010 (22); Smalheiser et al., 2014 (43) miR-211 Miller et al., 2009 (66); Sarachana et al., 2010 (62);
Vaishnavi et al., 2013 (67)
miR-148ba Moreau et al., 2011 (41); Shih et al., 2012 (84) miR-23a Abu-Elneel et al., 2008 (59); Talebizadeh et al., 2008 (61);
Sarachana et al., 2010 (62)
miR-15aa Moreau et al., 2011 (41); Shih et al., 2012 (84) miR-320a Abu-Elneel et al., 2008 (59); Talebizadeh et al., 2008 (61)
miR-17a Shih et al., 2012 (84); Smalheiser et al., 2014 (43) miR-429 Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-27b Moreau et al., 2011 (41); Shih et al., 2012 (84) miR-484 Abu-Elneel et al., 2008 (59); Vaishnavi et al., 2013 (67)
miR-29aa Kim et al., 2010 (22); Shih et al., 2012 (84) miR-598 Abu-Elneel et al., 2008 (59); Vaishnavi et al., 2013 (67)
miR-29c Shih et al., 2012 (84); Banigan et al., 2013 (44);
Smalheiser et al., 2014 (43)
miR-649 Vaishnavi et al., 2013 (67); Marrale et al., 2014 (68)
miR-874 Kim et al., 2010 (22); Miller et al., 2012 (42) miR-650 Ghahramani Seno et al., 2011 (63); Marrale et al., 2014 (68)
miR-92a-1 Kannu et al., 2013 (65); Hemmat et al., 2014 (64)
miR-93 Abu-Elneel et al., 2008 (59); Sarachana et al., 2010 (62)
These miRNAs have been associated with schizophrenia, bipolar disorder, major depressive disorder, or autism spectrum disorders by more
than one study.
miRNA, microRNA.
aMiRNA has been identiﬁed multiple times in more than one of these conditions.
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Miller et al. (42) observed the opposite in their microarray
analysis of BA46, with 10 miRNAs upregulated. More recently,
Smalheiser et al. (43) reported a fairly balanced distribution
using a TLDA array, with four miRNAs upregulated and ﬁve
miRNAs downregulated. Banigan et al. (44) analyzed the
miRNA content of exosomes from DLPFC (BA9) with a
Luminex Multiplex Assay (Luminex Corporation, Austin, Texas)
and qRT-PCR validation and discovered just one miRNA, miR-
29c, to be upregulated. The SNP rs1625579, which affects
miR-137 in SZ, was also found to be functionally associated
with individuals at risk of BD (45).
Although there is no direct evidence of dysregulated miRNA
biogenesis in BD, valproic acid has been shown to induce
proteasomal degradation of Dicer, which causes a general
downregulation of miRNA expression (46). These observations
suggest that this mood stabilizer used for treatment of BD may
have some inﬂuence on psychopathology through the mod-
iﬁcation of miRNA biogenesis.
Despite substantial heterogeneity of miRNA identiﬁed in
association with BD, a few miRNAs have appeared in multiple
studies (Table 1). Several of these miRNAs, including miR-29c,
miR-132, and miR-106b, have also been associated with SZ
suggesting there may be common pathways that are affected by
small RNA molecules in these psychotic syndromes. In partic-
ular, miR-132, mentioned earlier, has been implicated in the
circadian clock machinery, which is associated with BD and
depression (Supplement 1) (47). Further investigation of these
more robust miRNAs and their target genes should provide
insight into the development these disorders, and these miRNAs
could potentially serve as biomarkers and new drug targets.
MDD
The dysregulation of miRNAs has also been linked to MDD in
recent years (Table S1 in Supplement 1). One of the earliest
pieces of evidence for this link was the association between
depression and a SNP in the P2RX7 (purinergic receptor P2x,
ligand-gated ion channel 7) gene (48), which is reportedly
involved in modulating synaptic neurotransmission (49). This
SNP, rs1653625, occurs in the putative miRNA target site of
miR-1302 and miR-625 within the P2RX7 30 untranslated
region. Other SNPs associated with MDD by genotyping
include ss178077483, which is within the pre–miR-30e gene
and is associated with a longer P300 waveform latency, a
correlate of slower cognitive functioning (50), and two others in
the miRNA pathway genes AGO1 (Argonaute 1) (rs636832)
and DGCR8 (rs3757) (51). This link between miRNA pathway
gene polymorphisms and depression is particularly interesting
because a postmortem TLDA array study found a global
downregulation of miRNA species within BA9 of the DLPFC
in subjects exhibiting depression and suicidality (52). Although
this global downregulation hints at the possibility for alter-
ations in miRNA processing in the pathophysiology of depres-
sion, no changes in miRNA processing or DGCR8, DROSHA,
or DICER messenger RNA expression were observed.
A mouse model established in the same laboratory
assessed the difference in miRNA expression proﬁles between
mice that showed learned helplessness—an analogue for
depressive symptoms—and mice that did not show learnedBiological Psyhelplessness compared with controls after repeated, inescap-
able shock using another TLDA array approach (53). The
authors found that the mice that did not show learned help-
lessness demonstrated a signiﬁcant global downregulation of
miRNA expression as an adaptive response, whereas mice
that did show learned helplessness did not demonstrate
downregulation. The miRNAs included miR-96, miR-141,
miR-182, miR-183, miR-298, miR-200a/b/c, miR-322, and
miR-429. Three of these molecules, miR-96, miR-182, and
miR-183, are part of a polycistronic miRNA cluster that may be
involved in regulating genes in step with the circadian clock
(54); this is signiﬁcant because disruption of the circadian
rhythms is thought to be a factor in many disorders, including
depression (55). Taken together, these studies may suggest
that depressive symptoms brought about by excessive stress
are a result of a disrupted circadian clock via the perturbation
of its regulation by miRNAs.
As mentioned earlier, miR-132 has been associated with
many psychiatric illnesses. In one study, qRT-PCR analysis
found increased serum levels of miR-132 and miR-182 in
patients with depression (56). In addition, both miRNAs are
capable of downregulating brain-derived neurotrophic factor,
which was found at lower serum levels in the patients with
depression by enzyme-linked immunosorbent assay. The inter-
action of miR-132 with brain-derived neurotrophic factor as well
as with cyclic adenosine monophosphate response element
binding protein and glucocorticoids has been proposed to have
a signiﬁcant role in the development of some cases of depres-
sion as well as the comorbidity of cardiovascular diseases with
depression (57). Also, miR-132 has been implicated in regulating
the circadian clock (58), which is thought to be important in MDD.
ASDs
Direct evidence for miRNA involvement in ASDs is currently
very sparse; only a few studies have associated altered miRNA
expression levels in biological tissues with the incidence of
autistic traits (Table S1 in Supplement 1). One study identiﬁed
28 miRNA species that were dysregulated in postmortem
cerebellar cortex tissue in at least 1 of 13 subjects (59).
Among these miRNAs were miR-15a/b, miR-132, miR-212,
and miR-106b, which were mentioned previously in relation to
SZ and mood disorders. However, there has been some
contention over the validity of these data (60). Three other
studies investigated miRNA expression levels in lymphoblas-
toid cells by microarray analysis and found differentially
expressed miRNA species associated with autism (61–63).
The ﬁndings reported by Sarachana et al. (62) included the
dysregulation of miR-107, miR-195, and miR-106b, which
were also observed to be dysregulated in SZ. These studies
not only present a case for miRNA involvement in ASDs, but
they also further highlight the importance of a few miRNAs that
may be common to a range of psychiatric disorders.
In addition to these ﬁndings, a few studies have linked
CNVs of miRNA genes to ASDs and autistic traits. Two of
these studies identiﬁed the microduplication of the miR-17-92
cluster on chromosome 13q31.3—containing miR-17, miR-
18a, miR-19a, miR-19b-1, miR-20a, and miR-92a-1—in
patients with autistic traits (64,65). Autistic traits also have
been associated with miR-211 deletions and duplications atchiatry August 15, 2015; 78:231–239 www.sobp.org/journal 235
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investigators used CNV database searches and reported a
large number of miRNAs, including miR-211, that overlap with
known autism-associated CNVs (67,68). Again, miR-132 has
been associated with autism disorders several times, suggest-
ing it could be a particularly important miRNA (Supplement 1).
DISCUSSION
This review has highlighted the current evidence for aberrant
miRNA expression or function in four major neuropsychiatric
syndromes. Many of the miRNA species identiﬁed in these
studies have been characterized with regard to their functional
roles within neurons and their contribution to brain function.
Several miRNA species associated with these conditions are
involved in proliferation, differentiation, and maturation of
neurons, and their dysfunction may contribute to the neuro-
developmental deﬁcits seen in disorders such as SZ and
ASDs. Other miRNA species have roles in synaptic function
and may contribute to deﬁcits in glutamate and GABAergic
signaling seen in SZ, whereas still others, including miR-132,
are involved in the circadian clock pathways and have
implications for mood disorders. In addition, miR-132 and a
few other miRNA species have been associated with multiple
conditions on several occasions, making them particularly
interesting focal points for future research and possibly
making them useful in a clinical context.
Clinical Implications
There are two potential clinical applications of miRNAs: as a
diagnostic tool and as novel treatments. As discussed earlier,
numerous studies have already associated miRNA expression
in peripheral tissues with psychiatric disease. These miRNAs
have the potential to be biomarkers for these conditions.
Multiple studies of various psychiatric disorders have identiﬁed
miRNAs such as miR-132/212 and miR-15 family members
(Table 1), suggesting that these miRNAs may be particularly
useful in identifying individuals at risk of psychiatric disease.
However, given the wide range of miRNA species associated
with these conditions and the apparent heterogeneity, the use
of miRNAs as biomarkers remains a difﬁcult proposition.
The use of miRNAs or miRNA antagonist in the treatment of
psychiatric disorders is an appealing concept, particularly as
understanding about their function and roles in these con-
ditions increases. At the present time, these approaches are
limited by our capacity to deliver these molecules effectively.
Some progress has been made more recently in clinical trials
comprising patients with cancer receiving small interfering
RNA nanoparticles, which are chemically identical to synthetic
miRNAs, intravenously. These formulations successfully
downregulated the target messenger RNA and protein (69).
Inhibition of miRNAs in vivo has also been successful; cardiac
miR-15b expression was reduced in mice injected with anti-
miR-15b oligonucleotides (70). Manipulating miRNA in the
brain may not be as effective, as Krutzfeldt et al. (71)
discovered, with intravenous administration of anti-miR-16
unable to affect miRNA levels in the brain, whereas direct
injection into the cerebral cortex was effective. Intracerebro-
ventricular infusion of anti-miRNAs has been found to be an
effective delivery route, suggesting intrathecal delivery may be236 Biological Psychiatry August 15, 2015; 78:231–239 www.sobp.organ option (72,73). These studies demonstrate that miRNA or
their antagonists have the potential to be used as therapeutic
tools for the treatment of brain conditions, although the
feasibility of their delivery in the clinic needs to be addressed.Future Studies
Understanding of the role miRNAs play in brain function and
psychiatric disorders is still a growing ﬁeld. What is clear is
that the relationship between miRNA expression and these
conditions is complex; the dysregulation of numerous miRNA
species appears to correlate with these disorders. Some
miRNAs, such as miR-137, miR-132/212, and the miR-15
family, have been identiﬁed on multiple occasions, making
them particularly interesting targets for further research.
A better understanding of how miRNAs are differentially
expressed spatially and temporally throughout development
would aid in determining which miRNAs are the most impor-
tant for psychiatric disorders as well as at what stages during
development they contribute to disease. Some progress has
been made in this regard; a recent study identiﬁed changes to
the miRNA proﬁle across brain regions and through develop-
ment in samples from 18 normal individuals 4 months to 19
years old (74). A few of the miRNAs discussed here were
identiﬁed; miR-212 was downregulated from infancy to early
childhood in the DLPFC, and miR-137 was downregulated in
the same time frame in the cerebellar cortex. We also
investigated developmental changes in genome-wide miRNA
expression in the human DLPFC and found an interesting
inﬂection of miRNA expression during adolescence (75). More
recently, we explored the relationship between gene and
miRNA expression in the developing midbrain and hindbrain
of rat embryos and found signiﬁcant differences in the timing
of miRNA expression, particularly miR-132 and miR-137,
which accorded with the cortical maturity in the two regions
(76). Further research in normal healthy brain tissue in this way
will be invaluable for understanding how miRNAs contribute to
disease. Another important question is how miRNAs associ-
ated with psychiatric disorders are localized in individual
neurons. For example, localization to dendritic spines or axon
terminals may suggest a role in synaptic activity or neurite
growth and development. In this regard, miR-212 has been
observed enriched in axons, whereas miR-137 and miR-15
family members miR-195 and miR-16 were enriched in the cell
body (77). Dicer has been observed to localize in the cell body
and dendrites and at the Golgi complex and endoplasmic
reticulum of cerebellar granule neurons in vitro (78). The
combination of these high-resolution studies with the collec-
tion of data from large cohorts of postmortem samples and
genetic associations will greatly enhance understanding of the
role miRNAs play in neurobiology and psychiatric disorders.CONCLUSIONS
Research in the past decade suggests that miRNAs have a
signiﬁcant role to play in the function of the brain, and their
dysregulation and dysfunction may be part of the pathophysiol-
ogy of psychiatric disorders, including SZ, mood disorders, and
ASDs. Numerous studies have shown genetic associations of
miRNA genes and targets as well as altered expression levels in/journal
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Psychiatrythese syndromes. The association of DGCR8 dysregulation with
SZ and the association of SNPs in DGCR8 and AGO1 with MDD
add further weight to this hypothesis of miRNA involvement in
psychiatric disease, suggesting that, at least in some cases,
miRNA dysregulation on a global scale via abnormal biogenesis
may be involved in these conditions. The study of this relationship
between miRNA function and psychiatric disease is a growing
ﬁeld, and much of the information to date is preliminary, with
much still to be understood about the mechanisms by which
these small RNA molecules may inﬂuence the development of
psychiatric disease. However, these miRNAs are clearly important
in posttranscriptional organization of gene network structures that
are perturbed in complex disorders of the mind and may prove to
be useful tools for diagnosis and treatment of these disorders.ACKNOWLEDGMENTS AND DISCLOSURES
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